| Literature DB >> 22023067 |
Alvine Adrienne Kamdeu Fansi1, Jason Robert Guertin, Jacques LeLorier.
Abstract
OBJECTIVE: Antibiotic-associated diarrhea (AAD) and particularly Clostridium difficile-associated diarrhea (CDAD) are the most common causes of healthcare associated infectious diarrhea. A double-blind, dose response, placebo-controlled trial of the probiotic formula (Bio-K+ Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R formula) for prophylaxis of AAD and CDAD was published in 2010. The Bio-K+ Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R formula is a registered trademark of Bio-K Plus International Inc. (Laval, Québec, Canada). Results indicated that the incidence of AAD and CDAD were lower for patients assigned to the probiotic formula compared with the placebo option. The present study aims to estimate the savings in direct medical costs that might result from the use of two different doses of the probiotic formula vs placebo.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22023067 DOI: 10.3111/13696998.2011.629015
Source DB: PubMed Journal: J Med Econ ISSN: 1369-6998 Impact factor: 2.448